Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05150236
Title 177Lu-PSMA Therapy Versus 177Lu-PSMA in Combination With Ipilimumab and Nivolumab for Men With mCRPC (EVOLUTION) (EVOLUTION)
Acronym ANZUP2001
Recruitment Active, not recruiting
Gender male
Phase Phase II
Variant Requirements No
Sponsors Australian and New Zealand Urogenital and Prostate Cancer Trials Group
Indications
Therapies
Age Groups: adult | senior
Covered Countries AUS


No variant requirements are available.